Clinical trials: NASH (Nonalcoholic Steatohepatitis)
Nonalcoholic Fatty Liver Disease
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of a low free sugar diet on lipid profile, glycemic indices, liver enzymes, inflammatory factors and hepatic steatosis and fibrosis in patients with Nonalcoholic fatty liver disease, 50 patients who referred…
- Trial name
- NCT04369521
- Testing
- low free sugar diet
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Polycystic Ovarian Syndrome,, Nonalcoholic Fatty Liver Disease
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS
Since both pathologies (PCOS and NAFLD) involve disturbed carbohydrate economy, which revolve around insulin resistance, it is tempting to examine the specific "liver profile" of women with PCOD.
- Trial name
- NCT01735799
- Where
- Israel
- Sponsor
- Assy Nimer
Nonalcoholic Steatohepatitis
Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients
To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF)…
- Trial name
- NCT04462081
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
NAFLD (Non-Alcoholic Fatty Liver Disease), Resistance Training
The Role of Resistance Training in Non Alcoholic Fatty Liver Disease
The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.
- Trial name
- NCT01264198
- Testing
- Resistance Training
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
NAFLD
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence, linked to metabolic, cardiovascular and malignant morbidity and without any officially approved treatment.
- Trial name
- NAFTx (NCT04465032)
- Testing
- Gut microbiome transplantation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Depressive Disorder, Depression
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
The trial will be a four-arm, parallel group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks.
- Conditions
- Depressive Disorder, Depression, Anxiety, Stress
- Trial name
- PRO-DEMET (NCT04756544)
- Testing
- Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Lodz
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Non-alcoholic Steatohepatitis
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02912260
- Testing
- MGL-3196
- Where
- 26 sites in United States
- Volunteers
- 125 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic…
- Trial name
- EMPA-LIVER (NCT07915596)
- Testing
- Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
- Where
- Bangladesh
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Nonalcoholic Fatty Liver Disease
Time Restricted Feeding on Nonalcoholic Fatty Liver Disease
Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less.
- Trial name
- TREATY-FLD (NCT03786523)
- Testing
- Time restricted feeding, Continuous Energy Restriction
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
NAFLD, Pre-diabetes
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic…
- Trial name
- NCT02051842
- Testing
- Metadoxine
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
Healthy Liver - Healthy Brain
People with liver disease report difficulties with attention and problem-solving skills. Diet plays an important role in the development of liver disease and/or pre-diabetes.
- Conditions
- Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
- Trial name
- NCT05216796
- Testing
- Diet Intervention
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Non-alcoholic steatohepatitis (NASH) is an aggressive form of NAFLD with remarkable inflammatory features which may cause advanced fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Bariatric Surgery
- Trial name
- NCT04501042
- Testing
- Bariatric surgery
- Where
- Taiwan
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Nonalcoholic Fatty Liver Disease
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease.
- Trial name
- NCT06166797
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Non.Alcoholic Fatty Liver Disease
Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disorders characterized by predominantly macrovesicular hepatic steatosis occurring in individuals in the absence of significant alcohol consumption.
- Trial name
- NCT01623024
- Testing
- Vitamin D, Lifestyle counseling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Palermo
NAFLD, Steatosis of Liver
Response of NAFLD Patients to Mediterranean Diet
The effects of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis.
- Trial name
- NCT03203486
- Testing
- Mediterranean Diet
- Volunteers
- 44 people
- Sponsor
- Harokopio University
Fatty Liver, Fatty Liver, Nonalcoholic
The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease
The aim of this study is to evaluate the effects and safety of a dietary supplement, Zataria multiflora Boiss (Shirazi's Thyme) in the treatment of non alcoholic fatty liver disease (NAFLD).
- Trial name
- ThymeLiv (NCT02983669)
- Testing
- Thyme
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Shiraz University of Medical Sciences
NAFLD, Obesity
RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) in patients with diabetes (T2DM) is increasing in prevalence and can lead to cirrhosis.
- Conditions
- NAFLD, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT03365531
- Testing
- Alternate Daily Fasting (ADF), Caloric Restriction (CR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Fatty Liver, Obesity
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.
- Conditions
- Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD
- Trial name
- NICOFIB (NCT06599918)
- Testing
- Nicotinamide
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.